Disputes about patents come in all sizes. Some cases generate millions of documents, complex tests and hours of expert testimony, while other cases appear to involve few documents beyond the original patent application, the patent (if one was issued), and engineering or laboratory documents. A recent infringement lawsuit involving wound healing technology may quickly evolve from a minimal case into a complicated dispute involving four or more defendants.
The plaintiffs group includes a St. Louis company Acera Surgical, Inc., Retectix, LLC and Washington University. Acera is a small start-up company that has developed a wound healing technology that can be extremely valuable in medical applications. Acera has sued RenovoDerm, LLC and several related companies. The complaint alleges that the defendants have infringed on four of Acera’s patents that involve the use of nanofiber technology.
Acera’s principal business is the commercial marketing of devices that expedite the healing of surgical incisions and certain regenerative applications, including soft tissue repair. Retectix makes a similar line of products, and it was founded by Acera’s chief technology offer. The Food & Drug Administration has authorized the sale of two of Acera’s products.
The defendants have not yet filed an answer to the complaint. The case was filed in the United States District Court for the District of Delaware. As a start-up company, Acera has an especially vital interest in protecting its intellectual property. Any business that is pinning its initial hopes on one or two products must take every reasonable step to protect its proprietary information from infringement by competitors. Any business that feels that a competitor is stealing or using its intellectual property may wish to consult an experienced patent attorney about the possibility of commencing a lawsuit to recover damages and enjoin further infringement.